{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:47Z","timestamp":1793885687431,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":271,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005229","name":"Key Science and Technology Foundation of Gansu Province","doi-asserted-by":"publisher","award":["25JRRA818"],"award-info":[{"award-number":["25JRRA818"]}],"id":[{"id":"10.13039\/501100005229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou City Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023-ZD-170"],"award-info":[{"award-number":["2023-ZD-170"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017675","name":"Chinese People\u2019s Liberation Army","doi-asserted-by":"publisher","award":["2024-G3-5"],"award-info":[{"award-number":["2024-G3-5"]}],"id":[{"id":"10.13039\/501100017675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009620","name":"Gansu Province Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014993","name":"Central Military Commission of the People's Republic of China Logistic Support Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["24JRRA007"],"award-info":[{"award-number":["24JRRA007"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["25JRRA812"],"award-info":[{"award-number":["25JRRA812"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.rmcr.2026.102521","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:15:58Z","timestamp":1790694958000},"page":"102521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report"],"prefix":"10.1016","volume":"64","author":[{"given":"Lvdan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchen","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokang","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingliang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2026.102521_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-025-00455-5","article-title":"Antimelanoma differentiation-associated gene 5 (Anti-Mda5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort","volume":"9","author":"Koyoda","year":"2025","journal-title":"BMC RHEUMATOL"},{"key":"10.1016\/j.rmcr.2026.102521_bib2","first-page":"641","article-title":"Spontaneous intramuscular hemorrhage in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"8","author":"Mutoh","year":"2025","journal-title":"JMA journal"},{"key":"10.1016\/j.rmcr.2026.102521_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.882","article-title":"Clinical features and prognostic factors of anti\u2010melanoma differentiation\u2010associated gene 5 antibody\u2010positive dermatomyositis with rapidly progressive interstitial lung disease in Chinese patients","volume":"11","author":"Lian","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.rmcr.2026.102521_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-025-03485-z","article-title":"Clinical features and survival analysis of 40 cases of Anti-Mda5 antibody-positive dermatomyositis complicated with interstitial lung disease","volume":"27","author":"Zhao","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.rmcr.2026.102521_bib5","first-page":"55","article-title":"Two fatal cases of anti-melanoma differentiation-associated gene 5 antibody (Anti-Mda5) rapidly progressive interstitial lung disease (RP-ILD): exploring pitfalls and differences","author":"Ismail","year":"2025","journal-title":"RESPIR MED CASE REP"},{"key":"10.1016\/j.rmcr.2026.102521_bib6","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Yongpeng","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.rmcr.2026.102521_bib7","article-title":"Other iatrogenic immunodeficiency-associated lymphoproliferative disorders after multidrug immunosuppressive therapy for anti-melanoma differentiation association gene 5 antibody-positive dermatomyositis: a case report","volume":"9","author":"Mochizuki","year":"2025","journal-title":"MOD RHEUMATOL CASE"},{"key":"10.1016\/j.rmcr.2026.102521_bib8","article-title":"P300\/RNA polymerase II mediates induction of the teleost viral RNA sensor MDA5 through the interferon regulatory factor IRF11","author":"Li","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.rmcr.2026.102521_bib9","first-page":"13","article-title":"The intersection molecule MDA5 in cancer and COVID-19","author":"Jin","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.rmcr.2026.102521_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.rmcr.2026.102521_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.rmcr.2026.102521_bib12","first-page":"38","article-title":"Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases","author":"Mostkowska","year":"2024","journal-title":"FASEB J."},{"key":"10.1016\/j.rmcr.2026.102521_bib13","first-page":"41","article-title":"Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma Differentiation-Associatedprotein-5 antibody-positive dermatomyositis","author":"Shirai","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.rmcr.2026.102521_bib14","first-page":"57","article-title":"Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report","author":"Yen","year":"2021","journal-title":"MEDICINA-LITHUANIA"},{"key":"10.1016\/j.rmcr.2026.102521_bib15","first-page":"12","article-title":"Efficacy and safety of combined low-dose rituximab regimen for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Du","year":"2025","journal-title":"ANN CLIN TRANSL NEUR"},{"issue":"3","key":"10.1016\/j.rmcr.2026.102521_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14030709","article-title":"Management and prognosis of Anti-MDA5 dermatomyositis: insights from a national multicenter cohort","volume":"14","author":"Mogyorossy","year":"2026","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.rmcr.2026.102521_bib17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10067-025-07923-w","article-title":"The clinical values of laboratory inflammatory and composite indices in predicting rapidly progressive interstitial lung disease and prognosis in anti-MDA5 dermatomyositis patients","volume":"45","author":"Yu","year":"2026","journal-title":"CLIN RHEUMATOL. [Journal Article]"},{"key":"10.1016\/j.rmcr.2026.102521_bib18","article-title":"Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmcr.2026.102521_bib19","article-title":"Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review","volume":"62","author":"Xie","year":"2023","journal-title":"SEMIN ARTHRITIS RHEU. [Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review]"},{"issue":"12","key":"10.1016\/j.rmcr.2026.102521_bib20","first-page":"1049","article-title":"Triple-combination clindamycin phosphate 1.2%\/Adapalene 0.15%\/Benzoyl peroxide 3.1% gel for moderate-to-severe acne in children and adolescents","volume":"23","author":"Eichenfield","year":"2024","journal-title":"J DRUGS DERMATOL. [Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial]"},{"issue":"1","key":"10.1016\/j.rmcr.2026.102521_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0000000000000979","article-title":"New therapies in anti-MDA5 antibody-positive dermatomyositis","volume":"36","author":"Yasui","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.rmcr.2026.102521_bib22","article-title":"A shared monocyte cytokine signature induced by serum from patients with systemic lupus erythematosus and anti-MDA5 antibody-positive dermatomyositis through the type I interferon pathway","volume":"276","author":"Nakamura","year":"2025","journal-title":"Immunology Letters [Journal Article]"},{"issue":"13","key":"10.1016\/j.rmcr.2026.102521_bib23","first-page":"6472","article-title":"Murine coronavirus induces type I interferon in oligodendrocytes through recognition by RIG-I and MDA5","volume":"84","author":"Li","year":"2010","journal-title":"Journal of Virology [Journal Article; Research Support, NIH, Extramural; Research Support, Non-U.S. Gov't]"},{"key":"10.1016\/j.rmcr.2026.102521_bib24","article-title":"Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis","volume":"14","author":"Wang","year":"2023","journal-title":"FRONT IMMUNOL. [Journal Article; Research Support, Non-U.S. Gov't]"},{"issue":"5","key":"10.1016\/j.rmcr.2026.102521_bib25","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"European Respiratory Journal [Comparative Study; Journal Article; Multicenter Study]"},{"issue":"3","key":"10.1016\/j.rmcr.2026.102521_bib26","first-page":"406","article-title":"A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a phase 3 rheumatoid arthritis population","volume":"48","author":"Kivitz","year":"2018","journal-title":"SEMIN ARTHRITIS RHEU. [Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]"},{"issue":"6","key":"10.1016\/j.rmcr.2026.102521_bib27","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"CLIN RHEUMATOL. [Journal Article]"},{"issue":"7","key":"10.1016\/j.rmcr.2026.102521_bib28","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"CLIN RHEUMATOL. [Journal Article]"},{"key":"10.1016\/j.rmcr.2026.102521_bib29","first-page":"12","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","author":"He","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.rmcr.2026.102521_bib30","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ekir.2025.04.030","article-title":"Combination cyclophosphamide and rituximab to minimize glucocorticoid use in antineutrophil cytoplasm antibody-associated vasculitis","volume":"10","author":"Salehi","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.rmcr.2026.102521_bib31","article-title":"Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2022","journal-title":"FRONT PHARMACOL. [Journal Article; Systematic Review]"},{"issue":"4","key":"10.1016\/j.rmcr.2026.102521_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"RESP MED. [Journal Article]"},{"issue":"1","key":"10.1016\/j.rmcr.2026.102521_bib33","first-page":"61","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"CLIN PHARMACOKINET. [Journal Article; Research Support, Non-U.S. Gov't; Review]"},{"issue":"1","key":"10.1016\/j.rmcr.2026.102521_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-025-03675-7","article-title":"Tofacitinib treatment for psoriatic skin lesions associated with aicardi-goutieres syndrome 7\/Singleton-Merten syndrome 1","volume":"20","author":"Beerepoot","year":"2025","journal-title":"ORPHANET J RARE DIS. [Case Reports; Letter]"},{"key":"10.1016\/j.rmcr.2026.102521_bib35","first-page":"15","article-title":"Individualized therapy guided by single-cell sequencing in anti-gabaar encephalitis","author":"Shu","year":"2025","journal-title":"TRANSL PSYCHIAT"},{"key":"10.1016\/j.rmcr.2026.102521_bib36","first-page":"183","article-title":"Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)","volume":"2\/11","author":"Gruber","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.rmcr.2026.102521_bib37","first-page":"896","article-title":"Long-term treatment with azathioprine and mycophenolate Mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"CHEST. [Journal Article; Research Support, Non-U.S. Gov't]"},{"issue":"5","key":"10.1016\/j.rmcr.2026.102521_bib38","first-page":"640","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"The Journal of Rheumatology [Journal Article; Research Support, NIH, Extramural]"},{"key":"10.1016\/j.rmcr.2026.102521_bib39","first-page":"10","article-title":"Persistent B cell depletion after rituximab for autoimmune and glomerular diseases: a case series","author":"Efe","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.rmcr.2026.102521_bib40","first-page":"30","article-title":"Results from a phase 1 study of ACTR707 in combination with rituximab in patients with relapsed or refractory CD20+ B cell lymphoma","author":"Munoz","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.rmcr.2026.102521_bib41","article-title":"Low dose Vs conventional rituximab regimen in Pemphigus vulgaris - a retrospective single centre comparative analysis to assess the clinical efficacy and cost-effectiveness","volume":"16","author":"Kanagarajan","year":"2025","journal-title":"INDIAN DERMATOL ONL"},{"key":"10.1016\/j.rmcr.2026.102521_bib42","first-page":"29","article-title":"Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy","author":"Zheng","year":"2024","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.rmcr.2026.102521_bib43","first-page":"16","article-title":"Case report: exploring efficacy of tofacitinib in modulating interferon response in five case of Anti-Mda5+ dermatomyositis with interstitial lung disease","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmcr.2026.102521_bib44","article-title":"Are corticosteroids in intensive care immunosuppressive? Reflections and hypotheses","volume":"44","author":"K","year":"2025","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"10.1016\/j.rmcr.2026.102521_bib45","first-page":"24","article-title":"Intravenous immunoglobulin as a therapy for autoimmune conditions","volume":"2024\/11\/25","author":"Danieli","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.rmcr.2026.102521_bib46","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/IDR.S461206","article-title":"Clinical characteristics and epidemiological analysis of Pneumocystis jirovecii pneumonia infection in kidney transplant patients with trimethoprim-sulfamethoxazole dose reduction prophylaxis strategy","volume":"17","author":"Shan","year":"2024","journal-title":"Infect. Drug Resist."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007126001589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007126001589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:13:51Z","timestamp":1793884431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007126001589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":46,"alternative-id":["S2213007126001589"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102521","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102521"}}